|
1
|
Mitsudomi T: Advances in target therapy
for lung cancer. Jpn J Clin Oncol. 40:101–106. 2010. View Article : Google Scholar
|
|
2
|
Sun JM, Choi YL, Ji JH, Ahn JS, Kim KM,
Han J, Ahn MJ and Park K: Small-cell lung cancer detection in
never-smokers: Clinical characteristics and multigene mutation
profiling using targeted next-generation sequencing. Ann Oncol.
26:161–166. 2015. View Article : Google Scholar
|
|
3
|
Xu C, Zhou Q and Wu YL: Can EGFR-TKIs be
used in first line treatment for advanced non-small cell lung
cancer based on selection according to clinical factors? - A
literature-based meta-analysis. J Hematol Oncol. 5:622012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng DJ, Yu GH, Gao JF and Gu JD:
Concomitant EGFR inhibitors combined with radiation for treatment
of non-small cell lung carcinoma. Asian Pac J Cancer Prev.
14:4485–4494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schubert U, Antón LC, Gibbs J, Norbury CC,
Yewdell JW and Bennink JR: Rapid degradation of a large fraction of
newly synthesized proteins by proteasomes. Nature. 404:770–774.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yewdell JW and Nicchitta CV: The DRiP
hypothesis decennial: Support, controversy, refinement and
extension. Trends Immunol. 27:368–373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schröder M and Kaufman RJ: ER stress and
the unfolded protein response. Mutat Res. 569:29–63. 2005.
View Article : Google Scholar
|
|
8
|
van Anken E and Braakman I: Endoplasmic
reticulum stress and the making of a professional secretory cell.
Crit Rev Biochem Mol Biol. 40:269–283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van der Vlies D, Makkinje M, Jansens A,
Braakman I, Verkleij AJ, Wirtz KW and Post JA: Oxidation of ER
resident proteins upon oxidative stress: Effects of altering
cellular redox/antioxidant status and implications for protein
maturation. Antioxid Redox Signal. 5:381–387. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi Y, Vattem KM, Sood R, An J, Liang J,
Stramm L and Wek RC: Identification and characterization of
pancreatic eukaryotic initiation factor 2 alpha-subunit kinase,
PEK, involved in translational control. Mol Cell Biol.
18:7499–7509. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wek RC and Cavener DR: Translational
control and the unfolded protein response. Antioxid Redox Signal.
9:2357–2371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu L, Su L and Liu X: PKCδ regulates death
receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis
in human lung cancer cells. Mol Cancer Ther. 11:2174–2182. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yadav RK, Chae SW, Kim HR and Chae HJ:
Endoplasmic reticulum stress and cancer. J Cancer Prev. 19:75–88.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yap TA, Omlin A and de Bono JS:
Development of therapeutic combinations targeting major cancer
signaling pathways. J Clin Oncol. 31:1592–1605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang S: The promise of cancer therapeutics
targeting the TNF-related apoptosis-inducing ligand and TRAIL
receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Frew AJ, Lindemann RK, Martin BP, Clarke
CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P,
Stanley K, et al: Combination therapy of established cancer using a
histone deacetylase inhibitor and a TRAIL receptor agonist. Proc
Natl Acad Sci USA. 105:11317–11322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hellwig CT and Rehm M: TRAIL signaling and
synergy mechanisms used in TRAIL-based combination therapies. Mol
Cancer Ther. 11:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim J, Yun M, Kim EO, Jung DB, Won G, Kim
B, Jung JH and Kim SH: Generation of ROS by Decursin selectively
induces the ER stress pathway components ATF4/PERK leading to the
synergistic enhancement of TRAIL-induced apoptosis. Br J Pharmacol.
Dec 11–2015. View Article : Google Scholar : Epub ahead of
print.
|
|
19
|
Matsuzaki H, Schmied BM, Ulrich A, Standop
J, Schneider MB, Batra SK, Picha KS and Pour PM: Combination of
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and
actinomycin D induces apoptosis even in TRAIL-resistant human
pancreatic cancer cells. Clin Cancer Res. 7:407–414.
2001.PubMed/NCBI
|
|
20
|
Park D, Ha IJ, Park SY, Choi M, Lim SL,
Kim SH, Lee JH, Ahn KS, Yun M and Lee SG: Morusin induces TRAIL
sensitization by regulating EGFR and DR5 in human glioblastoma
cells. J Nat Prod. Feb 1–2016.Epub ahead of print. View Article : Google Scholar
|
|
21
|
Chiu SC, Huang SY, Chang SF, Chen SP, Chen
CC, Lin TH, Liu HH, Tsai TH, Lee SS, Pang CY, et al: Potential
therapeutic roles of tanshinone IIA in human bladder cancer cells.
Int J Mol Sci. 15:15622–15637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chiu TL and Su CC: Tanshinone IIA induces
apoptosis in human lung cancer A549 cells through the induction of
reactive oxygen species and decreasing the mitochondrial membrane
potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
|
|
23
|
Jiao JW and Wen F: Tanshinone IIA acts via
p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and
lung-resistance protein in cisplatin-resistant ovarian cancer
cells. Oncol Rep. 25:781–788. 2011.
|
|
24
|
Su CC and Lin YH: Tanshinone IIA inhibits
human breast cancer cells through increased Bax to Bcl-xL ratios.
Int J Mol Med. 22:357–361. 2008.PubMed/NCBI
|
|
25
|
Tseng PY, Lu WC, Hsieh MJ, Chien SY and
Chen MK: Tanshinone IIA induces apoptosis in human oral cancer KB
cells through a mitochondria-dependent pathway. BioMed Res Int.
2014:5405162014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jeon YJ, Kim JS, Hwang GH, Wu Z, Han HJ,
Park SH, Chang W, Kim LK, Lee YM, Liu KH, et al: Inhibition of
cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death
in hepatocellular carcinoma HepG2 cells. Eur J Pharmacol.
764:480–488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Munagala R, Aqil F, Jeyabalan J and Gupta
RC: Tanshinone IIA inhibits viral oncogene expression leading to
apoptosis and inhibition of cervical cancer. Cancer Lett.
356:536–546. 2015. View Article : Google Scholar
|
|
28
|
Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn
EJ, Yun M and Kim SH: Apoptosis induced by Tanshinone IIA and
crypto-tanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2
signaling in chronic myeloid leukemia K562 cells. Evid Based
Complement Alternat Med. 2013:8056392013. View Article : Google Scholar
|
|
29
|
Jin CY, Moon DO, Lee JD, Heo MS, Choi YH,
Lee CM, Park YM and Kim GY: Sulforaphane sensitizes tumor necrosis
factor-related apoptosis-inducing ligand-mediated apoptosis through
downregulation of ERK and Akt in lung adenocarcinoma A549 cells.
Carcinogenesis. 28:1058–1066. 2007. View Article : Google Scholar
|
|
30
|
La Monica S, Galetti M, Alfieri RR,
Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M,
Tagliaferri S, Mutti A, et al: Everolimus restores gefitinib
sensitivity in resistant non-small cell lung cancer cell lines.
Biochem Pharmacol. 78:460–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wallach D, Varfolomeev EE, Malinin NL,
Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor
receptor and Fas signaling mechanisms. Annu Rev Immunol.
17:331–367. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ozören N, Fisher MJ, Kim K, Liu CX, Genin
A, Shifman Y, Dicker DT, Spinner NB, Lisitsyn NA and El-Deiry WS:
Homozygous deletion of the death receptor DR4 gene in a
naso-pharyngeal cancer cell line is associated with TRAIL
resistance. Int J Oncol. 16:917–925. 2000.
|
|
33
|
Wang S and El-Deiry WS: Inducible
silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor
xenograft growth and confers resistance to chemotherapeutic agent
5-fluorouracil. Cancer Res. 64:6666–6672. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JY, Jung KH, Morgan MJ, Kang YR, Lee
HS, Koo GB, Hong SS, Kwon SW and Kim YS: Sensitization of
TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated
DR5 upregulation in human hepatocellular carcinoma cells. Mol
Cancer Ther. 12:274–285. 2013. View Article : Google Scholar
|
|
35
|
Oh YT, Liu X, Yue P, Kang S, Chen J,
Taunton J, Khuri FR and Sun SY: ERK/ribosomal S6 kinase (RSK)
signaling positively regulates death receptor 5 expression through
co-activation of CHOP and Elk1. J Biol Chem. 285:41310–41319. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamaguchi H and Wang HG: CHOP is involved
in endoplasmic reticulum stress-induced apoptosis by enhancing DR5
expression in human carcinoma cells. J Biol Chem. 279:45495–45502.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ackler S, Mitten MJ, Chen J, Clarin J,
Foster K, Jin S, Phillips DC, Schlessinger S, Wang B, Leverson JD,
et al: Navitoclax (ABT-263) and bendamustine ± rituximab induce
enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J
Pharmacol. 167:881–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang G, Zhan Y, Wang H and Li W: ABT-263
sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating
the Bcl-2 family of anti-apoptotic protein. Cancer Chemother
Pharmacol. 69:799–805. 2012. View Article : Google Scholar
|
|
39
|
Bleumink M, Köhler R, Giaisi M, Proksch P,
Krammer PH and Li-Weber M: Rocaglamide breaks TRAIL resistance in
HTLV-1-associated adult T-cell leukemia/lymphoma by translational
suppression of c-FLIP expression. Cell Death Differ. 18:362–370.
2011. View Article : Google Scholar :
|
|
40
|
Hasegawa H, Yamada Y, Komiyama K, Hayashi
M, Ishibashi M, Sunazuka T, Izuhara T, Sugahara K, Tsuruda K,
Masuda M, et al: A novel natural compound, a
cycloanthranilylproline derivative (Fuligocandin B), sensitizes
leukemia cells to apoptosis induced by tumor necrosis factor
related apoptosis-inducing ligand (TRAIL) through
15-deoxy-Delta12,14 prostaglandin J2
production. Blood. 110:1664–1674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park S, Cho DH, Andera L, Suh N and Kim I:
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by
regulating apoptosis-related proteins. Mol Cell Biochem. 383:39–48.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Seo OW, Kim JH, Lee KS, Lee KS, Kim JH,
Won MH, Ha KS, Kwon YG and Kim YM: Kurarinone promotes
TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP
expression in HeLa cells. Exp Mol Med. 44:653–664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tse AK, Chow KY, Cao HH, Cheng CY, Kwan
HY, Yu H, Zhu GY, Wu YC, Fong WF and Yu ZL: The herbal compound
cryptotanshinone restores sensitivity in cancer cells that are
resistant to the tumor necrosis factor-related apoptosis-inducing
ligand. J Biol Chem. 288:29923–29933. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chang CC, Kuan CP, Lin JY, Lai JS and Ho
TF: Tanshinone IIA facilitates TRAIL sensitization by up-regulating
DR5 through the ROS-JNK-CHOP signaling Axis in human ovarian
carcinoma cell lines. Chem Res Toxicol. 28:1574–1583. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin JY, Ke YM, Lai JS and Ho TF:
Tanshinone IIA enhances the effects of TRAIL by downregulating
survivin in human ovarian carcinoma cells. Phytomedicine.
22:929–938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Devasagayam TP, Tilak JC, Boloor KK, Sane
KS, Ghaskadbi SS and Lele RD: Free radicals and antioxidants in
human health: Current status and future prospects. J Assoc
Physicians India. 52:794–804. 2004.
|
|
47
|
Stadtman ER: Importance of individuality
in oxidative stress and aging. Free Radic Biol Med. 33:597–604.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen Y, Zhu J and Zhang W: Antitumor
effect of traditional Chinese herbal medicines against lung cancer.
Anticancer Drugs. 25:983–991. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gillissen B, Wendt J, Richter A, Richter
A, Müer A, Overkamp T, Gebhardt N, Preissner R, Belka C, Dörken B,
et al: Endogenous Bak inhibitors Mcl-1 and Bcl-xL: Differential
impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol.
188:851–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Johnson TR, Stone K, Nikrad M, Yeh T, Zong
WX, Thompson CB, Nesterov A and Kraft AS: The proteasome inhibitor
PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or
Bcl-xL overexpressing cells. Oncogene. 22:4953–4963. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lemke J, von Karstedt S, Abd El Hay M,
Conti A, Arce F, Montinaro A, Papenfuss K, El-Bahrawy MA and
Walczak H: Selective CDK9 inhibition overcomes TRAIL resistance by
concomitant suppression of cFlip and Mcl-1. Cell Death Differ.
21:491–502. 2014. View Article : Google Scholar :
|
|
52
|
Lirdprapamongkol K, Sakurai H, Abdelhamed
S, Yokoyama S, Athikomkulchai S, Viriyaroj A, Awale S, Ruchirawat
S, Svasti J and Saiki I: Chrysin overcomes TRAIL resistance of
cancer cells through Mcl-1 downregulation by inhibiting STAT3
phosphorylation. Int J Oncol. 43:329–337. 2013.PubMed/NCBI
|
|
53
|
Siegelin MD, Gaiser T, Habel A and
Siegelin Y: Daidzein overcomes TRAIL-resistance in malignant glioma
cells by modulating the expression of the intrinsic apoptotic
inhibitor, bcl-2. Neurosci Lett. 454:223–228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA,
Lim JH, Kwon TK and Choi KS: Monensin, a polyether ionophore
antibiotic, overcomes TRAIL resistance in glioma cells via
endoplasmic reticulum stress, DR5 upregulation and c-FLIP
downregulation. Carcinogenesis. 34:1918–1928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zang F, Wei X, Leng X, Yu M and Sun B:
C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast
cancer. Biochem Biophys Res Commun. 450:267–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Levy DE and Darnell JE Jr: Stats:
Transcriptional control and biological impact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
61
|
Song JI and Grandis JR: STAT signaling in
head and neck cancer. Oncogene. 19:2489–2495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
